Nephro and neurotoxicity of calcineurin inhibitors and mechanisms of rejections: A review on tacrolimus and cyclosporin in organ transplantation

Journal of Nephropathology

Volumn 1, Issue 1, 2012, Pages 23-30

  Tolou Ghamari, Zahra ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Immunosuppression; Organ transplantation; Rejection; Toxicity

Indexed keywords

EID: 84924989971     PISSN: 22518363     EISSN: 22518819     Source Type: Journal    
DOI: 10.5812/jnp.6     Document Type: Review

References (53)

1. Tolou-Ghamari. Monitoring tacrolimus (FK506) in liver transplant recipients: A consideration of alternative techniques and the influence of clinical status. 1998.
2. Cooper DK. A brief history of cross-species organ transplantation. Proc (Bayl Univ Med Cent). 2012;25(1):49-57.
3. Colombo D, Ammirati E. Cyclosporine in transplantation - a history of converging timelines. J Biol Regul Homeost Agents. 2011;25(4):493-504.
4. Kahan BD. The evolution of therapeutic immunosuppression and the potential impact of drug concentration monitoring. Ther Drug Monit. 1995;17(6):560-3.
5. Jaboulay M. Greffe de reins au pli du coude par soudures artérielles et veineuses. Lyon Med. 1906;107(39):575-83.
6. Calne R. The history and development of organ transplantation: biology and rejection. Baillieres Clin Gastroen terol. 1994;8(3):389-97.
7. Voronoy U. Sobre el bloqueo del aparato reticuloendotelial del hombre en algunas formas de intoxicaciom por el sublimado y sobre la transplantatacion del rinon cadaverico como metodo tratimiento de la anuria consecutive a aquella intoxication. 1937;97.
8. Starzl TE. France and the early history of organ transplantation. Perspect Biol Med. 1993;37(1):35-47.
9. Kuss R, Bourget P. An illustrated history of organ transplantation: the great adventure of the century. France: Laboratoires Sandoz, Rueil-Malmaison. 1992.
10. Kalayoglu M, D’Alessandro AM, Knechtle SJ, Sollinger HW, Pirsch JD, Hoffmann RM, et al. State of the art of liver transplantation in the USA. Transplant Proc. 1993;25(4 Suppl 3):47.
11. Tolou-Ghamari Z, Palizban A. The history of liver and renal transplantation. The Internet Journal of Pharmacology. 2003;2(1).
12. Patel SR, Smith NH, Kapp L, Zimring JC. Mechanisms of alloimmunization and subsequent bone marrow transplantation rejection induced by platelet transfusion in a murine model. Am J Transplant. 2012;12(5):1102-12.
13. Sis B, Jhangri GS, Riopel J, Chang J, de Freitas DG, Hidalgo L, et al. A new diagnostic algorithm for antibody-mediated microcirculation inflammation in kidney transplants. Am J Transplant. 2012;12(5):1168-79.
14. Suthanthiran M, Strom TB. Mechanisms and management of acute renal allograft rejection. Surg Clin North Am. 1998;78(1):77-94.
15. Gelb B, Feng S. Management of the liver transplant patient. Expert Rev Gastroenterol Hepatol. 2009;3(6):631-47.
16. Adams DH, Neuberger JM. Patterns of graft rejection following liver transplantation. J Hepatol. 1990;10(1):113-9.
17. Egawa H, Berquist W, So SK, Cox K, Menegaux F, Esquivel CO. Isolated alkaline phosphatemia following pediatric liver transplantation in the FK506 ERA. Transplantation. 1995;59(5):791-3.
18. Calmus Y. [Rejection of a liver allograft. Diagnosis and treatment]. Ann Radiol (Paris). 1994;37(5):377-82.
19. Kawabe T, Nakai T, Shindo K, Yasutomi M. Immunologic mechanism of rejection and graft-versus-host disease following orthotopic small intestinal transplantation in rats. Transplant Proc. 1998;30(1):27-8.
20. Critchley WR, Fildes JE. Graft rejection - endogenous or allogeneic? Immunology. 2012;136(2):123-32.
21. Pattison JM, Krensky AM. New insights into mechanisms of allograft rejection. Am J Med Sci. 1997;313(5):257-63.
22. Li W, Wu WW, Lin XS, Hou SX, Zhong HB, Ruan DK. Changes in T lymphocyte subsets and intracellular cytokines after transfer of chemically extracted acellular nerve allografts. Mol Med Report. 2012;5(4):1080-6.
23. Abadja F, Sarraj B, Ansari MJ. Significance of T helper 17 immunity in transplantation. Curr Opin Organ Transplant. 2012;17(1):8-14.
24. Kerzerho J, Yu ED, Barra CM, Alari-Pahisa E, Girardi E, Harrak Y, et al. Structural and functional characterization of a novel nonglycosidic type I NKT agonist with immunomodulatory properties. J Immunol. 2012;188(5):2254-65.
25. Teodorczyk-Injeyan JA, Sparkes BG, Mills GB, Peters WJ. Soluble interleukin 2-receptor alpha secretion is related to altered interleukin 2 production in thermally injured patients. Burns. 1991;17(4):290-5.
26. Wiesner RH, Ludwig J, Krom RA, Hay JE, van Hoek B. Hepatic allograft rejection: new developments in terminology, diagnosis, prevention, and treatment. Mayo Clin Proc. 1993;68(1):69-79.
27. Anderson BE, Tang AL, Wang Y, Froicu M, Rothstein D, McNiff JM, et al. Enhancing alloreactivity does not restore GVHD induction but augments skin graft rejection by CD4(+) effector memory T cells. Eur J Immunol. 2011;41(9):2782-92.
28. Gavin MA, Bevan MJ. Major histocompatibility complex allele-specific peptide libraries and identification of Tcell mimotopes. Methods Mol Biol. 1998;87:235-48.
29. Costantino CM, Spooner E, Ploegh HL, Hafler DA. Class II MHC self-antigen presentation in human B and T lymphocytes. PLoS One. 2012;7(1):e29805.
30. Cicora F, Roberti J, Lausada N, Gonzalez P, Guerrieri D, Stringa P, et al. [Immunosuppression in kidney donors with rapamycin and tacrolimus. Proinflammatory cytokine expression]. Medicina (B Aires). 2012;72(1):3-9.
31. Tolou-Ghamari Z, Wendon J, Tredger JM. In vitro pentamer formation as a biomarker of tacrolimus-related immunosuppressive activity after liver transplantation. Clin Chem Lab Med. 2000;38(11):1209-11.
32. Ostrov D, Krieger J, Sidney J, Sette A, Concannon P. T cell receptor antagonism mediated by interaction between T cell receptor junctional residues and peptide antigen analogues. J Immunol. 1993;150(10):4277-83.
33. Vanrenterghem YF. Impact of new immunosuppressive agents on late graft outcome. Kidney Int Suppl. 1997;63:S81-3.
34. Starzl TE. Liver transplantation. Gastroenterology. 1997;112(1):288-91.
35. Booth RA, Ansari MT, Loit E, Tricco AC, Weeks L, Doucette S, et al. Assessment of thiopurine S-methyltransferase activity in patients prescribed thiopurines: a systematic review. Ann Intern Med. 2011;154(12):814-23, W-295-8.
36. Bumgardner GL, Roberts JP. New immunosuppressive agents. Gastroenterol Clin North Am. 1993;22(2):421-49.
37. Lebreton L, Jost E, Carboni B, Annat J, Vaultier M, Dutartre P, et al. Structure-immunosuppressive activity relationships of new analogues of 15-deoxyspergualin. 2. Structural modifications of the spermidine moiety. J Med Chem. 1999;42(23):4749-63.
38. Musuamba FT, Mourad M, Haufroid V, Demeyer M, Capron A, Delattre IK, et al. A Simultaneous D-Optimal Designed Study for Population Pharmacokinetic Analyses of Mycophenolic Acid and Tacrolimus Early After Renal Transplantation. J Clin Pharmacol. 2011.
39. Ho S, Clipstone N, Timmermann L, Northrop J, Graef I, Fiorentino D, et al. The mechanism of action of cyclosporin A and FK 506. Clin Immunol Immunopathol. 1996;80(3 Pt 2):S40-5.
40. Tredger JM, Grevel J, Naoumov N, Steward CM, Niven AA, Whiting B, et al. Cyclosporine pharmacokinetics in liver transplant recipients: evaluation of results using both polyclonal radioimmunoassay and liquid chromatographic analysis. Eur J Clin Pharmacol. 1991;40(5):513-9.
41. Sommerer C, Giese T, Meuer S, Zeier M. New concepts to individualize calcineurin inhibitor therapy in renal allograft recipients. Saudi J Kidney Dis Transpl. 2010;21(6):1030-7.
42. TOLOUE GHAMARI Z, PALIZBAN A. LABORATORY MONITORING OF CYCLOSPORINE PREDOSE CONCENTRATION (C0) AFTER KIDNEY TRANSPLANTATION IN ISFAHAN. IRANIAN JOURNAL OF MEDICAL SCIENCES (IJMS). 2003;28(2):81-5.
43. Tolou-Ghamari Z, Palizban A, Gharavi M. Cyclosporin trough Concentration_Rejection relationship after kidney transplantation. Indian Journal of Pharmacology. 2003;35:395-96.
44. Gabe SM, Bjarnason I, Tolou-Ghamari Z, Tredger JM, Johnson PG, Barclay GR, et al. The effect of tacrolimus (FK506) on intestinal barrier function and cellular energy production in humans. Gastroenterology. 1998;115(1):67-74.
45. Akhlaghi F, Dostalek M, Falck P, Mendonza AE, Amundsen R, Gohh RY, et al. The concentration of cyclosporine metabolites is significantly lower in kidney transplant recipients with diabetes mellitus. Ther Drug Monit. 2012;34(1):38-45.
46. Thomson AW, Stephen ME, Woo J, Hasan NU, Whiting PH. Immunosuppressive activity, T-cell subset analysis, and acute toxicity of FK-506 in rats. Transplant Proc. 1989;21(1 Pt 1):1048-9.
47. Peters DH, Fitton A, Plosker GL, Faulds D. Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs. 1993;46(4):746-94.
48. Fukazawa K, Nishida S, Aguina L, Pretto E, Jr. Central pontine myelinolysis (CPM) associated with tacrolimus (FK506) after liver transplantation. Ann Transplant. 2011;16(3):139-42.
49. Penninga L, Moller CH, Gustafsson F, Steinbruchel DA, Gluud C. Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta-analyses and trial sequential analyses of randomised trials. Eur J Clin Pharmacol. 2010;66(12):1177-87.
50. Tolou-Ghamari Z, Palizban AA, Michael Tredger J. Clinical monitoring of tacrolimus after liver transplantation using pentamer formation assay and microparticle enzyme immunoassay. Drugs R D. 2004;5(1):17-22.
51. Tolou-Ghamari Z, Palizban AA. Kidney transplant recipients and the incidence of adverse reactions to cyclosporin. Saudi Med J. 2004;25(10):1499-500.
52. Tolou-Ghamari Z, Palizban A, Wendon J, Tredger J. Pharmacokinetics of Tacrolimus Immediately after Liver Transplantation. Transplantationsmedizin. 2004:112-6.
53. Tolou-Ghamari Z, Palizban A, Tredger J. Modelling Tacrolimus AUC in Acute and Chronic Liver Disease Immediately after Transplant. Transplantationsmedizin. 2004;16.